147

therapeutic
published patents

56

oncology
published patents

310

research tools

46

diagnostic
published patents

Our Technology Offers

Welcome to our Technology Offers website

You want access to an innovative offer which is based on the excellence of Inserm, the leading academic research and clinical institute dedicated to human health in Europe? Find out our technologies offers of patents and research tools: here is a sample of our patents.

Applications
Therapy areas
More posts

Methods and compositions for treating cell senescence accumulation

The inventors have surprisingly demonstrated that GD3 positive senescent cells inhibit NK cell in vitro and in vivo while GD3 negative senescent cells […]

New method to evaluate pancreatic prognosis

The present invention relates to the prediction of the survival time of a patient suffering of a pancreatic cancer. In this study, the inventors aimed […]

Methods for the diagnosis and treatment of t cell-lymphomas ccr8

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, […]

Method for diagnosing pancreatic cancer

The present invention relates to the diagnostics of pancreatic cancer. The inventors engineered a novel biomarker discovery approach, tailored for […]

Methods of determining whether a patient suffering froma

Pheochromocytomas produce and store catecholamines. The release of excessive amounts of catecholamine can lead to life-threatening […]

Method for pronosis and treating a patient suffering from cancer

Complement components form a plasma innate immune cascade but could also serve as multitasking proteins, as they have functions beyond this system. […]

Methods of assessing the risk of developing progressivemultifocal

Natalizumab a monoclonal antibody is associated with the risk of progressive multifocal leukoencephalopathy (PML), an infection caused by the John […]

New method to evaluate cancer prognosis

The present invention relates to the prediction and treatment of cancers. In this study, the inventors analyzed how invalidation of the mitochondrial […]

Use of cd9 as a biomarker and as a biotarget in glomerulonephritis

The mechanisms driving the development of extracapillary lesions in focal segmental glomerulosclerosis (FSGS) and crescentic glomerulonephritis (CGN) […]

Gdf3 as biomarker and biotarget in post-ischemic cardiac remodeling

Markers of an intense scarring process in the early phase post- myocardial infarction (MI) are still undetermined, and the identification of patients […]

More posts

You might also be interested in